| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99284 |
|
31,137 |
29,010 |
$6.54M |
| 99283 |
|
31,119 |
29,062 |
$4.73M |
| 87636 |
|
6,310 |
5,789 |
$1.02M |
| 99213 |
|
25,848 |
22,090 |
$694K |
| 99285 |
|
2,149 |
1,974 |
$669K |
| 71046 |
|
3,914 |
3,628 |
$220K |
| 85025 |
|
22,692 |
20,584 |
$173K |
| 96374 |
|
3,146 |
2,925 |
$134K |
| 93005 |
|
4,487 |
3,997 |
$134K |
| 80053 |
|
15,084 |
13,695 |
$133K |
| 99282 |
|
1,278 |
1,215 |
$101K |
| 74177 |
|
120 |
115 |
$89K |
| J3490 |
Unclassified drugs |
5,994 |
3,895 |
$72K |
| 70450 |
|
279 |
263 |
$69K |
| 36415 |
|
21,873 |
18,795 |
$64K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
2,866 |
2,495 |
$59K |
| 96375 |
|
978 |
899 |
$49K |
| G0378 |
Hospital observation service, per hour |
403 |
314 |
$46K |
| 96372 |
|
1,351 |
1,228 |
$45K |
| 87491 |
|
1,428 |
1,345 |
$43K |
| 87591 |
|
1,428 |
1,345 |
$43K |
| 96361 |
|
986 |
898 |
$39K |
| 80307 |
|
570 |
523 |
$36K |
| 87635 |
|
625 |
571 |
$34K |
| 41899 |
|
12 |
12 |
$30K |
| 80048 |
|
3,518 |
3,104 |
$29K |
| 87389 |
|
968 |
914 |
$29K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
2,059 |
1,861 |
$29K |
| 97597 |
|
718 |
354 |
$28K |
| 11042 |
|
395 |
186 |
$27K |
| 81025 |
|
3,075 |
2,829 |
$26K |
| 87804 |
|
3,261 |
1,692 |
$22K |
| A9270 |
Non-covered item or service |
57,465 |
27,464 |
$21K |
| 85027 |
|
3,071 |
2,755 |
$21K |
| 76816 |
|
262 |
246 |
$18K |
| 87430 |
|
932 |
885 |
$16K |
| 81001 |
|
4,472 |
4,176 |
$15K |
| 83690 |
|
1,722 |
1,610 |
$13K |
| 87426 |
|
352 |
317 |
$13K |
| 71045 |
|
248 |
233 |
$11K |
| 87631 |
|
131 |
123 |
$10K |
| J1050 |
Injection, medroxyprogesterone acetate, 1 mg |
92 |
89 |
$9K |
| 69436 |
|
41 |
40 |
$8K |
| J8499 |
Prescription drug, oral, non chemotherapeutic, nos |
3,157 |
2,070 |
$8K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
161 |
125 |
$7K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
1,474 |
1,333 |
$7K |
| 69210 |
|
224 |
219 |
$7K |
| 87880 |
|
462 |
453 |
$7K |
| 86803 |
|
312 |
297 |
$6K |
| 81002 |
|
2,060 |
1,526 |
$6K |
| 84484 |
|
578 |
514 |
$6K |
| 86850 |
|
279 |
266 |
$6K |
| 86592 |
|
1,027 |
971 |
$5K |
| 92567 |
|
235 |
227 |
$5K |
| 87088 |
|
486 |
459 |
$5K |
| 88305 |
|
81 |
77 |
$5K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
371 |
349 |
$4K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
565 |
538 |
$4K |
| 86762 |
|
209 |
199 |
$4K |
| 81003 |
|
1,742 |
1,622 |
$4K |
| 83036 |
|
315 |
302 |
$4K |
| 87340 |
|
277 |
265 |
$4K |
| 86787 |
|
198 |
188 |
$3K |
| 83735 |
|
454 |
420 |
$3K |
| 87632 |
|
22 |
19 |
$3K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
419 |
388 |
$3K |
| 87070 |
|
234 |
230 |
$2K |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
667 |
618 |
$2K |
| 87086 |
|
220 |
210 |
$2K |
| 86900 |
|
291 |
278 |
$2K |
| 86901 |
|
291 |
278 |
$2K |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
737 |
507 |
$2K |
| 90471 |
|
110 |
106 |
$2K |
| J7050 |
Infusion, normal saline solution, 250 cc |
352 |
83 |
$2K |
| 90792 |
|
98 |
68 |
$2K |
| 31231 |
|
26 |
26 |
$2K |
| 0001A |
|
24 |
24 |
$1K |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
738 |
713 |
$1K |
| 96365 |
|
13 |
12 |
$998.29 |
| 83655 |
|
60 |
55 |
$877.69 |
| 0002A |
|
14 |
14 |
$780.00 |
| 88142 |
|
28 |
28 |
$779.11 |
| 96360 |
|
14 |
14 |
$745.90 |
| 82950 |
|
114 |
104 |
$736.85 |
| 87798 |
|
22 |
19 |
$736.66 |
| 87486 |
|
22 |
19 |
$736.66 |
| 87081 |
|
69 |
59 |
$657.89 |
| 80061 |
|
58 |
57 |
$601.20 |
| Q3014 |
Telehealth originating site facility fee |
125 |
101 |
$561.38 |
| 83605 |
|
68 |
64 |
$534.90 |
| 83020 |
|
26 |
26 |
$524.24 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
83 |
80 |
$503.82 |
| 90686 |
|
29 |
28 |
$375.10 |
| 82105 |
|
12 |
12 |
$352.60 |
| 82248 |
|
55 |
52 |
$294.42 |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
12 |
12 |
$241.56 |
| J2704 |
Injection, propofol, 10 mg |
59 |
56 |
$212.39 |
| 82947 |
|
50 |
40 |
$208.70 |
| 80076 |
|
20 |
20 |
$205.56 |
| 86738 |
|
22 |
19 |
$202.57 |
| 84702 |
|
16 |
12 |
$183.48 |
| 96127 |
|
19 |
17 |
$168.00 |
| J2003 |
Injection, lidocaine hydrochloride, 1 mg |
48 |
33 |
$105.63 |
| 82728 |
|
14 |
12 |
$89.85 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
13 |
12 |
$83.82 |
| 84466 |
|
14 |
12 |
$79.55 |
| J2795 |
Injection, ropivacaine hydrochloride, 1 mg |
15 |
14 |
$43.05 |
| 83540 |
|
14 |
12 |
$40.40 |
| J0697 |
Injection, sterile cefuroxime sodium, per 750 mg |
12 |
12 |
$32.08 |
| J8597 |
Antiemetic drug, oral, not otherwise specified |
12 |
12 |
$23.03 |
| G1004 |
Clinical decision support mechanism national decision support company, as defined by the medicare appropriate use criteria program |
79 |
53 |
$0.00 |
| 91300 |
|
44 |
40 |
$0.00 |
| J0171 |
Injection, adrenalin, epinephrine, 0.1 mg |
12 |
12 |
$0.00 |
| 91301 |
|
13 |
13 |
$0.00 |